OraSure Technologies Inc. Common Stock (OSUR)

FairStock Score: 37/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I am looking for businesses whose earning power is durable and whose price is modest relative to that power. OraSure does not yet qualify. In fiscal 2023, the year ended 2023-12-31, it earned net income of $53.7 million on revenue of $405.5 million. By fiscal 2025, the year ended 2025-12-31, revenue had fallen to $115.0 million and the company lost $68.7 million. That is a COVID-era windfall reversing, not a stable franchise. What durable moat exists is not obvious from these numbers; the COVID surge was temporary, and diagnostic testing can be competitive. The latest fiscal Q2 2026, the quarter ended 2026-06-30, showed revenue of $30.6 million and net income of $6.2 million, so there may be a pulse, but fiscal Q1 2026, the quarter ended 2026-03-31, lost $22.4 million. The balance sheet is a genuine strength: debt-to-equity is only 0.04, and FairStock's Altman Z-Score is 3.54. At the 2026-10-13 close of $3.81, market cap is $262.8 million; FairStock calculates P/B of 0.83, a negative P/E, and trailing free cash flow of negative $48.1 million, an FCF yield of negative 18.3%. So the asset value may cushion, but cash is burning. Piotroski F-Score of 6/9 and FairStock Score of 37/100 suggest mediocre quality. The Lynch category is TURNAROUND, which fits. I would want evidence that recent profitability is repeatable before calling this cheap rather than merely depressed.

In plain English: OraSure makes rapid medical tests, including HIV and COVID-19 tests, and specimen collection devices. The business is much smaller and less profitable than it was during its COVID testing peak, and its latest full year showed a loss, though one recent quarter was profitable. At $3.81 a share, the price looks low compared with the company's assets minus debts, but with negative profits and cash burn it is not obviously a bargain.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer